Suzhou HVHa Medical Technology Development Co., Ltd. is committed to becoming a global leader in biosurgery technology. The company's mission is to build a biosurgery medical innovation technology platform, and its vision is to build a world-class, market-leading biosurgery technology company. Since its establishment in 2005, the company has focused on the research and development and application of cutting-edge fields such as biosurgery trauma repair,    orthopedic implants, and tissue engineering. We provide doctors with cutting-edge and efficient treatment solutions, surgical patients with better surgical treatment and better postoperative recovery, and improves the quality of life of patients, through a diversified product portfolio.

Relying on its five unique technology platforms - colloidal silver technology, hydrogel technology, bacterial cellulose technology, biological 3D technology and MT (metallothionein) technology, the company adheres to the trustworthy innovation concept, deeply explores the broad clinical needs, and forms a three-dimensional and full-coverage product structure with bacterial cellulose series products as the core, colloidal silver and hydrogel technology products, biological 3D technology products as auxiliary, Anong minimal invasive surgical instruments products as supplement, and metallothionein technology products as reserve.

The company's products cover a full range of products including hemostasis, surgical sealing, anti-adhesion, and soft tissue management. It has obtained more than 50 medical device registration certificates, including two Class III medical devices, and 5 of its products have been recognized as "innovative medical devices" by the National Medical Products Administration or provincial counterparts. Many of the company's products have unique advantages and leading positions in the domestic market, filling market gaps and improving the company's core competitiveness and industry recognition.

The company attaches great importance to R&D innovation and has established an excellent R&D system. It has a high-quality R&D team led by Academician Fu Xiaobing and Dr. Gu Yuanan, who is committed to the continuous development and research of biosurgical technology. So far, the company has obtained nearly 100 patents for core technologies, continuously promoted technological innovation and product upgrades, and injected strong impetus into the sustainable development of the company.

Looking to the future, the company will continue to uphold the development concept of "technology-led, innovation-driven" and continuously promote the innovation and progress of biosurgery technology. At the same time, the company will actively expand domestic and foreign markets, strengthen cooperation and exchanges with partners, jointly expand the space for the application of biosurgery technology, and continue to work hard for more equal human health!